Benzinga | Nov 15, 2021 11:11AM EST

UroGen Pharma Q3 EPS $(1.35) Misses $(1.29) Estimate, Sales $11.35M Miss $15.42M Estimate

UroGen Pharma (NASDAQ:URGN) reported quarterly losses of $(1.35) per share which missed the analyst consensus estimate of $(1.29) by 4.65 percent. This is a 3.05 percent decrease over losses of $(1.31) per share from the same period last year. The company reported quarterly sales of $11.35 million which missed the analyst consensus estimate of $15.42 million by 26.39 percent. This is a 227.97 percent increase over sales of $3.46 million the same period last year.